Endothelin-1 (EDN1) is a growth factor that is frequently produced by cancer cells and plays a critical role in tumorigenesis. However, the molecular mechanism controlling the expression of EDN1 in cancers is unknown. Constitutive activation of b-catenin pathway is responsible for the initiation of the vast majority of colon cancers. Here we show that the EDN1 gene is directly regulated by b-catenin in colon cancer cells. A specific DNA element within the EDN1 promoter is required for activation, and is associated with b-catenin's cognate DNA binding partner, TCF4, in vivo. Inhibition of b-catenin signaling results in lowered expression of EDN1, while enhancement of b-catenin signaling leads to further activation of the gene. Significantly elevated EDN1 expression occurs in 80% of primary human colon cancers, consistent with it being a direct target of b-catenin. Furthermore, EDN1 is able to rescue colon cancer cells from growth arrest and apoptosis resulting from inhibition of b-catenin signaling, implicating a key role of EDN1 in promoting the oncogenic function of b-catenin. These results indicate EDN1 overexpression as a major cause in colon cancers and reveal further details of the genetic programs responsible for tumorigenesis of colon cancers.
Introduction
EDN1 plays a key role in cell growth and differentiation, as well as in vascular homeostasis in mammals (Kedzierski and Yanagisawa, 2001; Nelson et al., 2003) . During embryonic development, EDN1 is produced by cephalic and cardiac neural crest stem cells to mediate proper differentiation of these cells into cranial facial and cardiac outflow structures (Kurihara et al., 1994; Kedzierski and Yanagisawa, 2001) . In adults, EDN1 is primarily expressed in vascular epithelial cells where it plays an important role in maintaining proper vascular tone (Yanagisawa et al., 1988; Kedzierski and Yanagisawa, 2001) .
EDN1 is frequently secreted by many solid tumors, including prostate, colorectal, liver, breast and ovarian cancers (Kusuhara et al., 1990; Nelson et al., 2003) . In these tumor cells, EDN1 has been shown to promote cell proliferation, suppress apoptosis, promote metastasis, and facilitate angiogenesis Grant et al., 2003; Nelson et al., 2003; Yin et al., 2003) . EDN1 exerts its diverse functions through two cellsurface receptors, EDNRA and EDNRB (Kedzierski and Yanagisawa, 2001) . In animal tumor models, endothelin receptor antagonists have demonstrated remarkable effects in suppressing tumor growth Rosano et al., 2003) . In clinical trials, these antagonists significantly delay the progression of metastasis in hormonal-refractory prostate cancers (Nelson, 2003) . These observations implicate abnormal expression of EDN1 to be a key step in tumorigenesis of many solid tumors.
Understanding the mechanisms of EDN1 expression in tumor cells may provide novel therapeutic strategies to inhibit initiation and progression of cancers. Currently, the molecular mechanisms responsible for pathological synthesis of EDN1 in tumor cells are not known. Unlike many oncogenes, no chromosomal translocations or amplifications of the EDN1 gene have been reported. It has been suggested that elevated levels of EDN1 are correlated with decreased levels of neural endopeptidase, the enzyme responsible for degradation and clearance of EDN1, in advanced prostate cancers (Papandreou et al., 1998) . However, both the EDN1 peptide and mRNA levels are shown to be elevated in colon cancers, indicating that transcriptional activation of the EDN1 gene is the likely mechanism of EDN1 overexpression in this cancer (Egidy et al., 2000) . We therefore hypothesized that EDN1 overexpression in colon cancers is a result of transcriptional activation by an oncogenic pathway.
Constitutive activation of b-catenin pathway is responsible for initiation of a majority of colon cancers Giles et al., 2003) . This pathway translates the growth-promoting signals of Wnt ligands to transcriptional activation of a diverse set of target genes. In normal cells, b-catenin is associated with E-cadherin and a-catenin to participate in cell-cell interaction. Free b-catenin is phosphorylated by the APC/Axin/GSK3b complex and targeted to proteasome-dependent degradation (Maniatis, 1999) . In response to Wnt signaling, free cytoplasmic b-catenin becomes stabilized, and is translocated into the nucleus where it complexes with the lymphoid enhancer factor/ T-cell factor (LEF/TCF) family of DNA binding proteins to activate the transcription of target genes (Bienz and Clevers, 2000; He, 2003) . In over 85% of colon cancer patients, the APC gene is inactivated by mutations resulting in constitutive activation of b-catenin pathway (Cohen, 2003) . Moreover, in APC positive colon cancer cases, the b-catenin gene is frequently mutated at the residues required for its targeting to proteasomal degradation Bienz and Clevers, 2000) . The activated b-catenin pathway is believed to initiate a tumorigenic program by promoting cell proliferation via activation of a target gene, MYC, and at the same time, protecting cells from apoptosis through regulation of unknown target genes (Giles et al., 2003) . Here, we demonstrate that b-catenin activates EDN1 expression in colon cancers, and that EDN1 expression contributes significantly to the survival of colon cancer cells.
Results
We employed a previously established genome-wide location analysis approach (Ren et al., 2000 (Ren et al., , 2002 Li et al., 2003) to examine the in vivo binding of TCF4 in a colorectal tumor cell line HT29-APC (Morin et al., 1996) . Our method involved crosslinking of cells with formaldehyde, extraction of chromatin and immunoprecipitation of protein/DNA complexes with a specific antibody against TCF4. The resulting TCF4-bound sites were identified by competitive hybridization of the fluorescently labeled DNA to a microarray containing B5000 known human gene promoters (Li et al., 2003) . We found the EDN1 promoter to be one of the most significantly enriched genomic regions by the TCF4 antibody (Po10
À5
). Sequence analysis of the EDN1 promoter revealed four potential TCF4 binding elements (TBE) (van de Wetering et al., 1991) within the 1 kb upstream of the transcriptional initiation site (Figure 1a) . We designed specific oligonucleotide primers to amplify each TBE containing DNA fragment and performed polymerase chain reactions (PCR) with these primers to test enrichment of each DNA fragment by the TCF4 antibody (aTCF4) in a conventional chromatin immunoprecipitation assay (ChIP) (Figure 1a ). This analysis indicated that the þ 1 fragment containing TBE3 and TBE4 was specifically precipitated with the aTCF4 antibody from crosslinked chromatin extracts, while fragments containing the upstream TBE1 and TBE2 were not (Figure 1b ). In addition, the association of TCF4 with the þ 1 fragment was not affected by APC induction (Figure 1b To determine whether the EDN1 promoter can be regulated by b-catenin signaling, we constructed a luciferase reporter with the EDN1 promoter sequence spanning À1362 to þ 165 bps surrounding the transcriptional initiation site. The activity of this reporter gene, when transfected into HT29-APC cells, was inhibited by co-transfecting a dorminant-negative inhibitor of TCF4 (Figure 1d ), indicating that the EDN1 promoter fragment is sufficient to confer responsiveness to b-catenin signaling to a heterologous gene. To determine which of the four TBE sites were actually responsible for TCF4 binding and activation, we introduced point mutations into each TBE (muTBE1-4, Figure 1a) , and transfected the mutant reporter constructs into HT29-APC cells. As shown in Figure 1e , transcriptional activity of the wild-type EDN1 promoter decreased more than three-fold upon APC induction. The mutations in TBE1-3 sites, while causing a two-fold reduction of EDN1 promoter activity, did not affect its response to b-catenin signaling. In contrast, mutation of TBE4 completely abolished the EDN1 promoter activity as well as its response to b-catenin signaling (Figure 1e ), highly consistent with the ChIP results ( Figure 1b ). This result indicated that TBE4 regulates EDN1 expression in response to b-catenin signaling.
To confirm that the mutations in TBE4 specifically affected the binding of TCF4 to this element, electrophoretic mobility shift assay (EMSA) was performed using recombinant TCF4 protein (Morin et al., 1997) . Consistent with the results from our transfection experiments, the recombinant TCF4 protein bound specifically to WT TBE4 DNA in a concentrationdependent manner. In contrast, TCF4 protein failed to bind to the mutated TBE4 ( Figure 1f ). We also performed the same experiment with the known TCF4 binding site within the MYC promoter (TBE1) as a control and observed a similar binding profile as the TBE4 element within the EDN1 promoter ( Figure 1g ). Together, these results suggest that b-catenin directly regulates the EDN1 promoter activity via TBE4 element in the EDN1 promoter.
Next, we examined whether endogenous EDN1 expression is indeed transcriptionally activated by b-catenin signaling, leading to elevated EDN1 protein levels in cancer cells. To test this hypothesis, we suppressed b-catenin signaling in HT29-APC cells by inducing expression of the wild-type APC transgene. The endogenous EDN1 mRNA level was reduced by more than 50% (Po0.01) upon APC induction. The extent of this reduction was similar to that of a known b-catenin target gene, MYC, under the same conditions ( Figure 2a ). Using HCT116 cells that are heterozygous for the wild-type b-catenin gene (Chan et al., 2002) , we tested whether activation of b-catenin signaling would induce transcription of the EDN1 gene by lithium (Li þ ) treatment. Li þ treatment is known to inhibit GSK3b, resulting in stabilization and activation of the endogenous wild-type b-catenin protein (Klein and Melton, 1996; Stambolic et al., 1996) in HCT116 cells. We observed a two-fold increase in EDN1 mRNA level upon Li þ treatment, comparable to the increased mRNA level observed for our positive control, MYC (Po0.01, Figure 2b ).
To determine if b-catenin regulated transcription of EDN1 actually resulted in regulated production of the matured EDN1 peptide, we performed enzyme-linked immunosorbent assays (ELISA). Consistent with transcriptional regulation of the EDN1 gene by b-catenin signaling, the level of secreted EDN1 peptide in HT29 cells was significantly reduced upon introduction of a dominant-negative mutant of TCF4 or b-catenin, while overexpression of wild-type b-catenin or TCF4 resulted in augmented EDN1 peptide production (Figure 2c ). Furthermore, siRNAs against either b-catenin or TCF4 inhibited production of EDN1 peptide in these cells (Po0.001, Figure 2d ). These results demonstrate that activity of b-catenin pathway is indeed required for high levels of EDN1 expression and production in colorectal cancer cells.
Since mutations in b-catenin pathway are one of the most frequent oncogenic events in human cancers and , we asked whether EDN1 mRNA levels are elevated at a high frequency in colon cancer patients. We examined EDN1 mRNA levels in colon cancer samples and matched normal colon tissues from human patients and found that significantly elevated levels (two-to 86-fold increase) of EDN1 mRNA were observed in 16 out of 20 tumor samples (Po0.05, Figure 3a and c) . Importantly, the reported frequency of EDN1 overexpression in human colon cancers is highly consistent with the combined, reported frequency of mutations that activate b-catenin signaling . We reasoned that the MYC gene, a well-known target of b-catenin signaling, would be also highly expressed in these tumor samples over normal tissues. Indeed, we found that MYC is overexpressed in 87.5% (14 out of 16) of the tumor tissues with elevated EDN1 expression (Po0.05, Figure 3b and c). These results provide a strong evidence for the direct role of b-catenin in EDN1 activation in human colon cancers.
To evaluate the functional significance of EDN1 expression in colon cancer cells, we investigated the effect of exogenous EDN1 peptide on growth of colon cancer cells upon inhibition of b-catenin signaling. Previous studies have shown that induction of the wild-type APC transgene by 100 mM ZnCl 2 in HT29-APC cells results in growth inhibition and apoptosis (Morin et al., 1996) , demonstrating the importance of b-catenin pathway in mediating cell proliferation and survival. EDN1 (100 pM) had little effect on the growth of HT29-APC cells in the absence of APC induction (Figure 4a and b) . However, we found that addition of exogenous EDN1 (100 pM) to the APC-induced, growth arrested cells resulted in restoration of their proliferation and protection from apoptosis ( Figure 4a) . This effect appears to be largely mediated by EDN1 through suppressing cell death; 36% of the APC induced cells were dead, but addition of exogenous EDN1 reduced the dead cells to only 8% of the population, similar to level observed for untreated cells (Figure 4b ). Previously, it was shown that MYC is a major effecter of cell growth from b-catenin signaling, and reactivation of MYC by EDN1 would be a simple explanation of our findings (van de Wetering et al., 2002) . To determine if MYC reactivation by EDN1 may be the reason for the protective effect of EDN1, we investigated the MYC mRNA levels in these cells. Although EDN1 alone can slightly augment MYC expression, when APC is induced and exogenous EDN1 is added, the MYC mRNA level remained at a level observed when only APC is induced, to a level less than 50% of the control cells (Figure 4c) . Therefore, EDN1 suppression of APC induced cell death is likely through a MYC-independent mechanism. From these results and previous observations that endothelin receptor antagonists block proliferation and induce apoptosis of HT29 cells (Peduto Eberl et al., 2003) , we conclude that activation of EDN1 expression is an essential aspect of b-catenin pathway in maintaining the growth and survival of colon cancer cells.
Discussion
Based on these findings, we propose that the frequent overexpression of the EDN1 gene in human colon cancers is a direct consequence of genetic alterations of b-catenin signaling in these tumors. Inactivating mutations in the APC gene or activating mutations in b-catenin lead to the formation of b-catenin/TCF4 complex on the EDN1 promoter, which in turn activates transcription of the gene. EDN1 would contribute to b-catenin's oncogenic program by providing antiapoptotic and growth-promoting functions.
Many target genes for the b-catenin pathway have been previously identified (http://www.stanford.edu/ rnusse/wntwindow.html). One such target gene, MYC, appears to play a central role by suppressing expression of the cyclin-dependent kinase inhibitor p21 and by promoting cell proliferation (van de Wetering et al., 2002) . In addition to its role in proliferation, MYC is known to induce apoptosis by activating expression of proapoptotic genes (Pelengaris et al., 2002 (Shichiri et al., 1998) . Similarly, EDN1 can also protect FasL-induced apoptosis in colorectal cancer cells (Peduto Eberl et al., 2003) . In our study, EDN1 can rescue colon cancer cells from cell death resulting from inhibition of b-catenin pathway (Figure 4b) . A possible mechanism of EDN1 mediated suppression of cell death may involve activation of AKT by EDN1 as shown in ovarian carcinoma cells (Del Bufalo et al., 2002) .
Our results demonstrate b-catenin as a key regulator of EDN1 and provide a framework for understanding the molecular basis of frequent EDN1 activation in human cancer cells. Besides colon cancers, EDN1 overexpression has been reported for a number of other cancers including prostate, breast, liver, and skin cancers. Coincidentally, genetic lesions in APC, Axin, and b-catenin genes have also been observed in all these solid tumors. It would be interesting to test whether overexpression of EDN1 in these other cancer tissues is a result of activation of b-catenin pathway.
Materials and methods

Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as described previously (Li et al., 2003) . Briefly, 2 mg of sonicated chromatin (OD 260 ) was incubated with 10 mg of mouse monoclonal TCF4 antibody (Upstate Biotechnology, Charlottesville, VA, USA) coupled to the sheep anti-mouse IgG magnetic beads (Dynal Biotech, Lake Success, NY, USA). The magnetic beads were washed eight times with RIPA buffer containing 50 mM HEPES (pH 8.0), 1 mM EDTA, 1% NP-40, 0.7% DOC, and 0.5 M LiCl, supplemented with Completet protease inhibitors (Roche Applied Science, Indianapolis, IN, USA), and washed once with TE (10 mM Tris pH 8.0, 1 mM EDTA). After washing, the bound DNA was eluted by heating the beads to 651C in elution buffer (10 mM Tris, pH 8.0, 1 mM EDTA, and 1% SDS). The eluted DNA was incubated at 651C for 12 more hours to reverse the crosslinks. Following incubation, the immunoprecipitated DNA was desalted using QIAquick s PCR purification kit (Qiagen, Valencia, CA, USA). The purified DNA was blunt ended using T4 polymerase (New England Biolabs, Beverly, MA, USA) and ligated to the linkers (oJW102, 5 0 -GCGGTGACCCGGGA-GATCTGAATTC-3 0 ; and oJW103, 5 0 -GAATTCAGATC-3 0 ) (Ren et al., 2000) . The ligated DNA was subjected to ligation mediated PCR, labeled with Cy3 and Cy5 dCTP using BioPrimer s DNA labeling kit (Invitrogen, Carlsbad, CA, USA), and hybridized to the DNA microarray containing the previously described B5000 unique human promoters (Li et al., 2003) . The immunoprecipitated DNA was subjected to an end point PCR analysis using primers designed to amplify the specific regions of the EDN1 promoter (À7, À1 kb, and TATA regions) and a control genomic region (À10 kb upstream of the CAD gene). The PCR was performed on a DNA Engine Tetrad thermal cycler (MJ Research, Waltham, MA, USA) using cycling parameters of 5 min at 941C followed by 35 cycles of 1 min at 941C, 30 s at 601C and 1 min at 721C. The following primer pairs were used for the PCR of the ChIP DNA: À7K_Left, 5 0 -CCTTT GCCACAGCTCCTAAA-3 0 , and À7K_Right, 5 0 -ACAATGA TTGGGGTGAGGAA-3 0 ; À1K_Left, 5 0 -CATCAGCCCCTGT AGCTCTT-3 0 , and À1K_Right, 5 0 -CATGCCCAGTCTTTTC CCTA-3 0 ; TATA_Left, 5 0 -GGCAGAGAGCTGTCCAAGT C-3 0 , and TATA_Right, 5 0 -CGGGTTCCTCAGATCTCAA A-3 0 ; and CTRL_Left, 5 0 -TGGGTTTGGTAGGGGACATA-3 0 , and CTRL_Right, 5 0 -CTGGGCTCTGCTGGCTTA-3 0 .
Reporter constructs
The EDN1 promoter sequence spanning À1362 to þ 165 bps surrounding the transcriptional initiation site was amplified from human genomic DNA by PCR using the primers, 5 0 -CTC GAGGTTCCATGCACCTTTTGCTT-3 0 and 5 0 -AAGCTTC CCAAAGGAAAACGAAGAAAA-3 0 . The EDN1 promoter PCR fragment was restriction enzyme digested with XhoI and BamHI (New England Biolabs, Beverly, MA, USA) and cloned into the XhoI and BamHI acceptor sites within the pGL2 luciferase reporter (Promega, Madison, WI, USA). Mutations within the potential TCF4 binding elements (TBE1-4) were introduced by site-directed mutagenesis using the QuickChange s kit (Invitrogen, Carlsbad, CA, USA). The primers used for site-directed mutagenesis were the following pairs: muTBE1_S, 5 0 -CTGTGTGAAAAACACTTTTACTTT TCAATCAGTTTATCAGCCTCCTCCGC-3 0 , and muTBE1_AS, 5 0 -GCGGAGGAGGCTGATAAACTGATTGAAAAGTAA AAGTGTTTTTCACACAG-3 0 ; muTBE2_S, 5 0 -GCACGGG-CAGGTTTAGTAAAAGTCTCTAATGGG-3 0 , and muTB E2_AS, 5
0 -CCCATTAGAGACTTTTACTAAACCTGCCC GTGC-3 0 ; muTBE3_S, 5 0 -GCGGGTTCCTCAGATCTTAA GGCGATCCTTCAGCCC-3 0 , and muTBE3_AS, 5 0 -GCGGG TTCCTCAGATCTTAAGGCGATCCTTCAGCCC-3 0 ; and muTBE4_S, 5 0 -GAGGAACCCGCAGCGCCTTAAGGGAC CTGAAGCTGTTTTTCTTCG-3 0 , and muTBE4_AS, 5 0 -CG AAGAAAAACAGCTTCAGGTCCCTTAAGGCGCTGCG GGTTCCTC-3 0 .
Transfections and ELISA
Transient transfection experiments were performed using Lipofectaminet 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA), as described by the manufacturer. Briefly, HT29-APC cells were seeded at 1 Â 10 5 cells in each well of 24-well plate 24 h prior to transfection. Each luciferase reporter DNA (0.6 mg) was combined with 0.2 mg of CMV-lacZ control reporter DNA and mixed with 3 ml of Lipofectaminet 2000 in Opti-MEM s media (Invitrogen, Carlsbad, CA, USA). The DNA-Lipofectamine mixture was placed into each well. After 24 h post-transfection, media was replaced and cells were induced with 100 mM ZnCl 2 . After 12 h postinduction, cells were harvested, and the luciferase and b-galactosidase activity were determined using Dual-Light s luciferase and b-galactosidase reporter gene assay system (Tropix, Bedford, MA, USA) on a luminometer. Relative reporter activities were determined by normalizing the luciferase activity to the corresponding b-galactosidase activity.
Synthesized siRNA oligos against b-catenin mRNA (target sequence: 5 0 -AAAGCUGAUAUUGAUGGACAG-3 0 ) and TCF4 mRNA (SMARTpool) were obtained commercially (Dharmacon RNA Technologies, Lafayette, CO, USA). Cells cultured in 24-well dish were transfected with double-stranded siRNA oligos (5 nM/well) using Lipofectaminet 2000 transfection reagent in triplicate. After 36 h post-transfection, the cell culture medium was collected for ELISA. Cell extracts were analysed for the effectiveness of RNAi by immunoblotting with b-catenin (BD Biosciences Pharmingen, San Diego, CA, USA) and TCF4 (Upstate Biotechnology, Charlottesville, VA, USA) antibodies. The expression plasmids encoding b-catenin and TCF4 variants were described previously (Roose et al., 1999; van de Wetering et al., 2002) . These plasmids were transfected into cells using Lipofectaminet 2000 transfection reagent. After 36 h post-transfection, the cell culture medium b-Catenin activates endothelin-1 in colon cancer cells TH Kim et al was collected for ELISA. The secreted EDN1 levels in the culture supernatants were determined in triplicate using an endothelin-1 ELISA kit (R&D Systems, Minneapolis, MN, USA). ELISA was performed according to the instruction provided by the manufacturer.
EMSA
Electrophoresis mobility shift assays were performed using a recombinant GST-TCF4 protein, and doubled stranded oligo with the following sequences. Double stranded oligos of the wild-type TBE4 (5 0 -GAGGAACCCGCAGCGCTTTGAGG-GACCTGAAGCTGTTTTTCTTCG-3 0 ) or muTBE4 (5 0 -GA GGAACCCGCAGCGCCTTAAGGGACCTGAAGCTGTT TTTCTTCG-3 0 ) from the EDN1 promoter or the wild-type TBE1 (5 0 -CTAGCGCACCTTTGATTTCTGCACCTTTGAT TTCTG-3 0 ) or muTBE1 (5 0 -CTAGCGCACCTTTGGCTTC TGCACCTTTGGCTTCTG-3 0 ) from MYC promoter (Morin et al., 1996) were used for EMSA. The recombinant GST-TCF4 protein was purified from Escherechia coli. An E. coli DE3 strain, transformed with the pGEX-TCF4 plasmid (He et al., 1998) , was grown to OD 600 of 0.5, induced with 1 mM IPTG, and grown for additional 4 h at 301C. The induced cells were harvested by centrifugation, and the cell pellet was washed with PBS. The cells were lysed by sonication in PBS with 5% glycerol and Completet protease inhibitors. The cell lysate was clarified by centrifugation and incubated with 1 ml GST-Sepharose 4B resin (Amersham Biosciences, Piscataway, NJ, USA) in batch at 41C for 2 h. The resin was transferred to a disposable Econocolumnt (Bio-Rad Laboratories, Hercules, CA, USA) and washed in the column with 20 ml PBS. The bound proteins were eluted with 10 mM glutathione (Amersham Biosciences, Piscataway, NJ, USA), and dialysed in PBS with 10% glycerol. A serial dilution of the GST-TCF protein (0.125, 0.25, 0.5 and 1.0 mg) was incubated with 1.5 pmol of oligo in binding buffer (12.5 mM HEPES, pH 8.0, 50 mM NaCl, 5 mM DTT, 5% glycerol, and 1 mg/ml BSA) for 30 min at room temperature. The reaction mixture was loaded onto 6% (29 : 1 mono : bis) polyacrylamide gel containing 1 Â TBE (89 mM Tris, 89 mM boric acid, and 2 mM EDTA). The polyacrylamide gel was subjected to electric current of 5 V/ cm for 1 h at room temperature, stained with SYBR green I DNA dye (Molecular Probes, Eugene, OR, USA), and visualized under UV illumination.
Quantitative real-time PCR
Total RNA from cultured colon cancer cells and primary tissue samples were prepared using Trizol s reagent (Invitrogen, Carlsbad, CA, USA). Total RNA from HT29-APC cells was prepared from cells treated with or without 100 mM ZnCl 2 for 12 h. Total RNA from HCT116 cells was prepared after treating the cells with 20 mM LiCl for 36 h. Total RNA from primary human tissues was prepared by gentle sonication to disperse the solid tissue in Trizol s reagent. cDNA was synthesized from 50 mg of total RNA using poly-dT 16 primer and Superscript s II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). After cDNA synthesis, RNase A was added to reaction to hydrolyse RNA, and the remaining cDNA was purified using QIAquick s PCR purification kit, and 25 ng of cDNA was used as templates for quantitative real-time PCR.
The primers, 5 0 -TGGGAAAAAGTGTATTTATCAGCA-3 0 and 5 0 -TTTGACGCTGTTTCTCATGG-3 0 were used to amplify the EDN1 mRNA. The primers, 5 0 -CTGGTGC TCCATGAGGAGA-3 0 and 5 0 -CTCTGACCTTTTGCCAG GAG-3 0 were used to amplify the MYC mRNA. The primers, 5 0 -GCAAAGACCTGTACGCCAAC-3 0 and 5 0 -ACACCGAG TACTTGCGCTCT-3 0 were used to amplify a reference gene, the gamma actin (ACTG1) mRNA. The quantitative real-time PCR of each sample was performed in triplicate using iCyclert and SYBR green iQt SYBR green supermix reagent (Bio-Rad Laboratories, Hercules, CA, USA , the relative EDN1 mRNA levels in the tumor (or induced) sample compared to normal (or uninduced) sample were determined.
Proliferation and FACS analysis
HT29-APC cells were seeded in six-well plates at 1 Â 10 5 cells/ wells in triplicate for each treatment. Next day, the media was replaced, and 100 pM EDN1 (EMD Biosciences, San Diego, CA, USA), 100 mM ZnCl 2 , or combined 100 pM EDN1 and 100 mM ZnCl 2 was added directly to cells. After 72 h post-treatment, cells were carefully washed twice with PBS and fixed using 1% paraformaldehyde in PBS for 15 min at room temperature. The fixed cells were washed twice with PBS and were stained with 0.5% crystal violet (w/v in ethanol) for 15 min at room temperature. The stained cells were thoroughly but gently washed with dH 2 O and dried and visualized by digital photography. FACS analyses were performed with the cells at 72 h posttreatment, were harvested and fixed with 80% ethanol at 41C for 24 h. The fixed cells were treated with 40 mg/ml RNase A and stained with 20 mg/ml propidium iodide in dH 2 O. The stained cells were analysed by FACS using Becton Dickson FACSort instrument (BD Biosciences Immunocytometry Systems, San Jose, CA, USA). G1, G2, S, and dead cells were determined from the generated FACS dataset for each treatment using ModFit software (Verity Software House, Topsham, ME, USA).
